In this “Letters to Blood,” the author demonstrated that luspatercept provided prolonged periods of transfusion independence (TI), significantly decreased the transfusion burden among HTB and LTB patients, and generally had an acceptable and predictable safety profile, all of which helped to maintain or enhance patient quality of life. Compared to the results from the primary analysis, these data further demonstrate the clinical benefits of luspatercept in patients with LR-MDS-RS.

These specialties had the highest proportion of doctors still making student loan payments, per the 2022 Medscape report: Emergency Medicine (31%) Physical Medicine & Rehabilitation (31%) Pediatrics (31%) Neurology (28%) Otolaryngology (28%) Family Medicine (28%) For the least debt-burdened: Pulmonary Medicine (10%) Public Health & Preventive Medicine (11%) Rheumatology (12%) Diabetes & Endocrinology (15%) Dermatology (16%) Cardiology (16%)

A review of the seven zones/14 stations as defined by the International Association for the Study of Lung Cancer (IASLC): Supraclavicular zone Station 1 (left/right): low cervical, supraclavicular, and sternal notch nodes Upper zone (superior mediastinal nodes) Station 2 (left/right): upper paratracheal nodes Station 3A and 3P: pre-vascular and retrotracheal nodes Station 4 (left/right): lower paratracheal nodes Aortopulmonary zone Station 5: subaortic nodes (aortopulmonary window) Station 6: para-aortic nodes, ascending aorta or phrenic Subcarinal zone Station 7: subcarinal nodes Lower zone (inferior mediastinal nodes) Station 8 (left/right): para-esophageal nodes (below carina) Station 9 (left/right): pulmonary ligament nodes Hilar and interlobar zone (pulmonary nodes) Station 10 (left/right): hilar nodes Station 11: interlobar nodes Peripheral zone (pulmonary nodes) Station 12: lobar nodes Station 13: segmental nodes Station 14: subsegmental nodes

According to a survey conducted by the Association for Clinical Oncology, the majority of respondents (96%) said prior authorization has led to delays in cancer treatment, with 80% claiming prior authorization has enabled disease progression, and 36% of them saying prior authorization has led to patient deaths. 300 ASCO members who work in academic or university (29%) settings, private practice (34%), or community or hospital-based health network/systems (35%), completed the survey.

Four-hundred seventy-three of 713 patients were randomly assigned to receive durvalumab; 236 received a placebo. The 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The median progression-free survival from randomization was 16.8 months with durvalumab versus 5.6 months with placebo. Durvalumab had a response rate that was higher than placebo (28.4% vs. 16.0%), and the median response time was also longer (72.8% vs. 46.8% of the patients continued to have a response at 18 months). Durvalumab extended the median time to death or distant metastasis compared to placebo (23.2 months vs. 14.6 months). 29.9% of patients who received durvalumab and 26.1% of patients who received a placebo experienced adverse events of grade 3 or 4.

The study looks at outcomes of people who came down with COVID during the infection’s first wave. Fatigue, pain, and memory loss were the most common persistent symptoms, in that order.